Impaired wound healing secondary to bevacizumab

Bevacizumab is a monoclonal antibody that exerts its antitumor activity by inhibiting vascular endothelial growth factor. Consequently, it suppresses endothelial cell proliferation, vascular permeability, and angiogenesis. This inhibitory effect contributes to tumour size reduction but causes wound‐...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Int Wound J
Prif Awduron: Ahn, Ji W., Shalabi, Doaa, Correa‐Selm, Lilia M., Dasgeb, Bahar, Nikbakht, Neda, Cha, Jisun
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Blackwell Publishing Ltd 2019
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948921/
https://ncbi.nlm.nih.gov/pubmed/31111622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/iwj.13139
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg